451 related articles for article (PubMed ID: 24200276)
1. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
[TBL] [Abstract][Full Text] [Related]
3. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
[TBL] [Abstract][Full Text] [Related]
4. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
Kumar AK; Chandrasekaran V; Kannan T; Murali AL; Lavanya J; Sudha V; Swaminathan S; Ramachandran G
Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients.
Babalık A; Ulus IH; Bakirci N; Kuyucu T; Arpag H; Dagyildiz L; Çarpaner E
Int J Tuberc Lung Dis; 2013 Nov; 17(11):1442-7. PubMed ID: 24125448
[TBL] [Abstract][Full Text] [Related]
6. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
[TBL] [Abstract][Full Text] [Related]
7. Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs.
Kumar AKH; Chandrasekaran V; Kumar AK; Kawaskar M; Lavanya J; Swaminathan S; Ramachandran G
Indian J Med Res; 2017 Apr; 145(4):530-535. PubMed ID: 28862186
[TBL] [Abstract][Full Text] [Related]
8. Pyrazinamide serum levels in childhood tuberculosis.
Thee S; Detjen A; Wahn U; Magdorf K
Int J Tuberc Lung Dis; 2008 Sep; 12(9):1099-101. PubMed ID: 18713511
[TBL] [Abstract][Full Text] [Related]
9. Penetration of isoniazid, rifampicin and pyrazinamide in tuberculous pleural effusion and psoas abscess.
Jutte PC; Rutgers SR; Van Altena R; Uges DR; Van Horn JR
Int J Tuberc Lung Dis; 2004 Nov; 8(11):1368-72. PubMed ID: 15581207
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence of fixed-dose combination Myrin®-P Forte and reference drugs in loose combination.
Wang HF; Wang R; O'Gorman M; Crownover P; Naqvi A; Jafri I
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1596-601. PubMed ID: 24200275
[TBL] [Abstract][Full Text] [Related]
11. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients.
Kimerling ME; Phillips P; Patterson P; Hall M; Robinson CA; Dunlap NE
Chest; 1998 May; 113(5):1178-83. PubMed ID: 9596291
[TBL] [Abstract][Full Text] [Related]
12. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
13. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
Ramachandran G; Kumar AK; Kannan T; Bhavani PK; Kumar SR; Gangadevi NP; Banurekha VV; Sudha V; Venkatesh S; Ravichandran N; Kalpana S; Mathevan G; Sanjeeva GN; Agarwal D; Swaminathan S
Pediatr Infect Dis J; 2016 May; 35(5):530-4. PubMed ID: 26825153
[TBL] [Abstract][Full Text] [Related]
14. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
Park JS; Lee JY; Lee YJ; Kim SJ; Cho YJ; Yoon HI; Lee CT; Song J; Lee JH
Antimicrob Agents Chemother; 2016 Jan; 60(1):92-8. PubMed ID: 26459901
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.
Hemanth Kumar AK; Kannan T; Chandrasekaran V; Sudha V; Vijayakumar A; Ramesh K; Lavanya J; Swaminathan S; Ramachandran G
Int J Tuberc Lung Dis; 2016 Sep; 20(9):1236-41. PubMed ID: 27510252
[TBL] [Abstract][Full Text] [Related]
16. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
Thee S; Seddon JA; Donald PR; Seifart HI; Werely CJ; Hesseling AC; Rosenkranz B; Roll S; Magdorf K; Schaaf HS
Antimicrob Agents Chemother; 2011 Dec; 55(12):5560-7. PubMed ID: 21968358
[TBL] [Abstract][Full Text] [Related]
18. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
Padgaonkar KA; Revankar SN; Bhatt AD; Vaz JA; Desai ND; D'Sa S; Shah V; Gandewar K
Int J Tuberc Lung Dis; 1999 Jul; 3(7):627-31. PubMed ID: 10423226
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring in the treatment of tuberculosis patients.
Magis-Escurra C; van den Boogaard J; Ijdema D; Boeree M; Aarnoutse R
Pulm Pharmacol Ther; 2012 Feb; 25(1):83-6. PubMed ID: 22179055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
